Share price up 2p today LSE Market News8 Dec 2020 10:29
Genedrive PLC - near patient molecular diagnostics company - Notes completion of the Antibiotic Induced Hearing Loss implementation study into the use of the genetic test in an NHS neonatal intensive care setting. Company adds: "The Genedrive MT-RNR1 ID Kit has been used over the past 11 months in a trial of what is thought to be a world first use of a genetic test in a neonatal intensive care setting. The Genedrive assay has been used at Manchester University NHS Foundation Trust and Liverpool Women's Hospital to screen babies before administering certain antibiotics that are known to cause deafness in infants." Chief Executive David Budd says completion of study is "major milestone".